These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 16773408

  • 41. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
    Zhang M, Qi C, Zha Y, Chen J, Luo P, Wang L, Sun Z, Wan J, Xing C, Wang S, Jiang G, Sun M, Chen Q, Chen J, Li D, Guan T, Ni Z.
    Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
    [Abstract] [Full Text] [Related]

  • 42. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
    Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H.
    Ren Fail; 2008 Mar; 30(9):865-9. PubMed ID: 18925525
    [Abstract] [Full Text] [Related]

  • 43. An unusual case of systemic lupus erythematosus, lupus nephritis, and transient monoclonal gammopathy.
    Strobel ES, Fritschka E, Schmitt-Gräff A, Peter HH.
    Rheumatol Int; 2000 Mar; 19(6):235-41. PubMed ID: 11063295
    [Abstract] [Full Text] [Related]

  • 44. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S, Berden JH, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Dutch Working Party on SLE.
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [Abstract] [Full Text] [Related]

  • 45. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
    F L, Y T, X P, L W, H W, Z S, H Z, Z H, MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group.
    Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
    [Abstract] [Full Text] [Related]

  • 46. [Laboratory and morphologic parameters in patients with lupus nephritis].
    Rasković S, Bogić M, Perić-Popadić A, Stefanović L, Arandjelović S, Jovicić Z, Bolpacić J, Tomić-Spirić V.
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
    [Abstract] [Full Text] [Related]

  • 47. Mizoribine requires individual dosing due to variation of bioavailability.
    Fuke T, Abe Y, Hibino S, Takeshi M, Saito T, Sakurai S, Watanabe S, Murayama J, Itabashi K, Nakano Y.
    Pediatr Int; 2012 Dec; 54(6):885-91. PubMed ID: 23039376
    [Abstract] [Full Text] [Related]

  • 48. Mizoribine: a new approach in the treatment of renal disease.
    Kawasaki Y.
    Clin Dev Immunol; 2009 Dec; 2009():681482. PubMed ID: 20052390
    [Abstract] [Full Text] [Related]

  • 49. [Effect of methylprednisolone pulse therapy in patients with lupus nephritis assessed by WHO morphologic classification].
    Makino H, Yamasaki Y, Hayashi Y, Haramoto T, Shikata K, Kumagai I, Taniai K, Takahashi K, Ota Z.
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):791-9. PubMed ID: 2273595
    [Abstract] [Full Text] [Related]

  • 50. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria.
    Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, Oryoji K, Shimoda T, Niiro H, Tada Y, Yano T, Nonaka T, Oishi R, Akashi K, Horiuchi T.
    Clin Exp Rheumatol; 2010 Jul; 28(1):6-12. PubMed ID: 20346231
    [Abstract] [Full Text] [Related]

  • 51. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 52. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
    Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Gang W, Li PK.
    Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
    [Abstract] [Full Text] [Related]

  • 53. Effective treatment with cyclosporine A of a child with systemic lupus erythematosus resistant to cyclophosphamide pulse therapy.
    Suzuki K, Tanaka H, Tsugawa K, Ito E.
    Tohoku J Exp Med; 2006 Apr; 208(4):355-9. PubMed ID: 16565599
    [Abstract] [Full Text] [Related]

  • 54. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.
    Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT.
    Arthritis Rheum; 2002 Apr; 46(4):995-1002. PubMed ID: 11953977
    [Abstract] [Full Text] [Related]

  • 55. Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
    Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A.
    Mod Rheumatol; 2018 May; 28(3):523-529. PubMed ID: 28753077
    [Abstract] [Full Text] [Related]

  • 56. What happens after complete withdrawal of therapy in patients with lupus nephritis.
    Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C.
    Clin Exp Rheumatol; 2013 May; 31(4 Suppl 78):S75-81. PubMed ID: 24129143
    [Abstract] [Full Text] [Related]

  • 57. Pharmacokinetic study of mizoribine in child-onset glomerulonephritis.
    Abe Y, Mikawa T, Fuke T, Hisano M, Tsuji Y, Watanabe S, Itabashi K.
    Pediatr Int; 2008 Oct; 50(5):615-9. PubMed ID: 19261105
    [Abstract] [Full Text] [Related]

  • 58. Long-term mizoribine intermittent pulse therapy, but not azathioprine therapy, attenuated histologic progression in a patient with severe lupus nephritis.
    Tanaka H, Tsugawa K, Oki E, Suzuki K, Waga S, Ito E.
    Clin Nephrol; 2007 Sep; 68(3):198-200. PubMed ID: 17915627
    [No Abstract] [Full Text] [Related]

  • 59. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].
    Cai XY, Yang XY, Chen XH, Liang LQ, Guan MM, Qin SG, Fu JZ.
    Zhonghua Yi Xue Za Zhi; 2004 Sep 02; 84(17):1436-9. PubMed ID: 15500738
    [Abstract] [Full Text] [Related]

  • 60. Mizoribine and mycophenolate mofetil.
    Ishikawa H.
    Curr Med Chem; 1999 Jul 02; 6(7):575-97. PubMed ID: 10390602
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.